Physician profile
Stephen Solomon
NPI 1245326602
$5,176.76
in general payments reported to CMS, 2019-2025
22 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 83% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.59 · 2020: $17.20 · 2021: $201 · 2022: $457 · 2023: $1,377 · 2024: $1,386 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426 · Education: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,425.62 |
| Education | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,893.48 | 2022-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $710.88 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $468.46 | 2022-2023 | Uplizna, Tepezza |
| Janssen Biotech, INC. | $417.37 | 2025 | Tremfya |
| Amgen INC. | $411.47 | 2024-2025 | Uplizna, Tepezza |
| Pfizer INC. | $350.07 | 2023-2025 | |
| Ucb, INC. | $282.68 | 2023-2025 | Rystiggo |
| Biohaven Pharmaceuticals, INC. | $176.63 | 2021 | |
| Lundbeck LLC | $74.61 | 2023-2025 | Vyepti |
| Lilly USA, LLC | $62.24 | 2022-2023 | Emgality |
| Dompe US, INC. | $49.91 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $41.29 | 2019-2020 | |
| Axsome Therapeutics, INC. | $36.75 | 2025 | Symbravo |
| Azurity Pharmaceuticals, INC. | $32.37 | 2024 | Zonisade |
| Boston Scientific Corporation | $30.90 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $24.10 | 2024 | Quzyttir |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.06 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $22.69 | 2025 | |
| Abbvie INC. | $22.30 | 2023 | Durysta |
| Novartis Pharmaceuticals Corporation | $19.09 | 2019 | |
| Staar Surgical Company | $13.29 | 2019 | |
| Allergan, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.